The screen was performed in TP53-positive and -deficient cells and they identified the lack of BRCA1/2 and RAD6/RAD18-dependent DNA repair pathways to enhance the sensitivity of TP53-deficient tumor cells to cisplatin. The gene discussed is TP53; the disease is neoplasm.